About Quetyx Therapeutics
Quetyx Therapeutics is dedicated to developing innovative cutaneous medicines that address unmet needs in dermatology. Founded by industry veterans, our team leverages decades of expertise to advance the science of skin therapies and improve patient outcomes. Our pipeline includes multiple drug candidates that have progressed beyond Proof-of-Concept, reflecting our commitment to scientific achievement and patient care.
Pioneering Dermatological Innovation
Through rigorous clinical research and a passion for innovation, we create dermatology solutions that transform lives. Our approach integrates scientific rigor, patient-centric design, and a relentless drive to bring new therapies to market.
Our Leadership Team
Our leadership team comprises seasoned professionals with deep expertise in pharmaceutical development, clinical research, and dermatology. Their vision and experience drive Quetyx Therapeutics forward.
Zengquan Wang, PhD
Founder/ Board Chairman
○ Over 30 years of skin disease research and drug development
○ Founder, Chairman, and CEO at Technoderma Medicines Inc.
○ Chief Business Officer, Viva Biotech
○ AstraZeneca Respiratory & Inflammation Area, PSII (Director level), ICC China
○ Pfizer Ann Arbor, Anaderm Associate Research Fellow; Pfizer St. Louis, Inflammation therapeutic area Associate Research Fellow
○ Research Investigator, OSI Pharmaceuticals
○ Faculty in Dermatology, University of Michigan School of Medicine
○ PhD Washington State University
Arthur P. Bertolino MD, PhD, MBA
Founder/ CEO and Chief Medical Officer
○ Over 25 years Pharmaceutical drug development
○ CEO and Chief Medical Officer at Innovation Dermatologics Inc.
○ Chief Medical Officer at Technoderma Medicines Inc. and CytoAgents Inc.
○ Director (Board), President and CMO of Innovation Pharmaceuticals Inc.
○ VP of Dermatology and VP & Global Head of Translational Medicine for Dermatology, NIBR — Ilaris® (canakinumab) & Cosentyx™ (secukinumab)
○ Senior Med Director and Senior Director of Dermatology at Pfizer
○ CMO & VP of Medical Affairs at Peplin, Inc. – Picato® (ingenol mebutate)
○ Executive VP & CMO at Revance Therapeutics; DAXXIFY™
○ BS, SUNY Stony Brook, MD and PhD in Pharmacology from Johns Hopkins University, and MBA, University of Michigan Stephen M. Ross School of Business
Partner With Us to Advance Dermatology
Connect with our team to learn more about our innovative therapies, research collaborations, and investment opportunities.